References
  1. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA 2020 Mar 25th, online first publication. DOI: 10.1001/jamacardio.2020.0950.
  2. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Feb 7th, online first. DOI: 10.1001/jama.2020.1585.
  3. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J 2020 Mar 16th online first publication. DOI: 10.1093/eurheartj/ehaa190.
  4. Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses 2017;11:372-393.
  5. Alexander LK, Small JD, Edwards S, Baric RS. An experimental model for dilated cardiomyopathy after rabbit coronavirus infection. J Infect Dis 1992;166:978-85.
  6. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020 Mar 18th, online first publication. DOI: 10.1093/eurheartj/ehaa231.
  7. Yu CM, Wong RS, Wu EB, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J 2006;82:140-4.
  8. Lau ST, Yu WC, Mok NS, Tsui PT, Tong WL, Cheng SW. Tachycardia amongst subjects recovering from severe acute respiratory syndrome (SARS). Int J Cardiol 2005;100:167-9.
  9. Pan SF, Zhang HY, Li CS, Wang C. Cardiac arrest in severe acute respiratory syndrome: analysis of 15 cases. Zhonghua Jie He He Hu Xi Za Zhi. 2003;26:602-5.
  10. Centers for Disease Control and Prevention (CDC). Update: Severe respiratory illness associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-worldwide, 2012-2013. MMWR Morb Mortal Wkly Rep 2013;62:480-3.
  11. Maslow JN. Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus. Hum Vaccin Immunother. 2017;13:2918-2930.
  12. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis 2016;49:129-33.
  13. Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014;29:301-6.
  14. Al-Abdallat MM, Payne DC, Alqasrawi S, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 2014;59:1225-33.
  15. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016;36:78-80.
  16. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal Influenza Infections and Cardiovascular Disease Mortality. AMA Cardiol 2016;1:274-81.
  17. Madjid M, Connolly AT, Nabutovsky Y, Safavi-Naeini P, Razavi M, Miller CC. Effect of High Influenza Activity on Risk of Ventricular Arrhythmias Requiring Therapy in Patients With Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators. Am J Cardiol 2019;124:44-50.
  18. Ang LW, Yap J, Lee V, et al. Influenza-Associated Hospitalizations for Cardiovascular Diseases in the Tropics. Am J Epidemiol 2017;186:202-209.
  19. Modin D, Jørgensen ME, Gislason G, et al. Influenza Vaccine in Heart Failure. Circulation. 2019;139:575-586.
  20. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
  21. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020 Mar 27th, online first publication DOI: 10.1001/jamacardio.2020.1017.
  22. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-1062.
  23. Li SS, Cheng C, Fu C, et al. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation 2003;108:1798-803.
  24. Harris JE, Shah PJ, Korimilli V, Win H. Frequency of troponin elevations in patients with influenza infection during the 2017–2018 influenza season. Int J Cardiol Heart Vasc 2019;22:145-147.
  25. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020 Mar 12th, online first publication. DOI: 10.1016/j.ijid.2020.03.017.
  26. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 Mar 5th, online first publication. DOI: 10.1038/s41569-020-0360-5.
  27. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SAR. Eur J Clin Invest 2009;39:618-25.
  28. Wong CK, Lam CW, Wu AK, et al . Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004;136:95-103.
  29. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008;133:13-9.
  30. Yang C, Jin Z. An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic—COVID-19 and Cardiovascular Diseases. JAMA Cardiol 2020 March 25th, online first publication. DOI:10.1001/jamacardio.2020.0934.
  31. Ratliff NB, Estes ML, McMahon JT, Myles JL. Chloroquine-induced cardiomyopathy. Arch Pathol Lab Med 1988;112:578.
  32. Seshadri MS, John L, Varkey K, Koshy TS. Ventricular tachycardia in a patient on dehydroemetine and chloroquine for amoebic liver abscess. Med J Aust 1979;1:406-7.
  33. Fauchier JP, Fauchier L, Babuty D, Breuillac JC, Cosnay P, Rouesnel P. Drug-induced ventricular tachycardia. Arch Mal Coeur Vaiss 1993;86:757-67.
  34. Siqueira-Batista R, Ramos Júnior AN, Pessanha BS, Sforza-de-Almeida MP, Potsch DF. Chloroquine and cardiac arrhythmia: case report. East Afr Med J 1998;75:117-9.
  35. Harris L, Downar E, Shaikh NA, Chen T. Antiarrhythmic potential of chloroquine: new use for an old drug. Can J Cardiolo 1988;4:295-300.
  36. Verny C, de Gennes C, Sebastien P, et al. Heart conduction disorders in long-term treatment with chloroquine: two new cases. Presse Med 1992;2:800-4.
  37. Capel RA, Herring N, Kalla M, et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. Heart Rhythm 2015;12:2186-94.
  38. O’Laughlin JP, Mehta PH, Wong BC. Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine. Case Rep Cardiol 2016;2016:4626279.
  39. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-94.
  40. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801-9.
  41. Al-Tawfiq JA, Hinedi K, Ghandour J, et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis 2014;59:160-5.
  42. Schoen K, Horvat N, Guerreiro NFC, de Castro I, de Giassi KS. Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity. BMC Infect Dis 2019;19:964.
  43. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013;13:752-61.
  44. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020 Mar 27th, online first publication. DOI: 10.1001/jamacardio.2020.1096.
Table 1. Cohorts that evaluated cardiac manifestations in SARS-CoV, MERS-CoV, H1N1, and SARS-CoV-2